New hope for young hodgkin patients: drug combo aims to cut radiation
NCT ID NCT06563245
First seen Mar 21, 2026 · Last updated May 23, 2026 · Updated 10 times
Summary
This study tests a new treatment for children, teens, and young adults (ages 2 to 34) with newly diagnosed classical Hodgkin lymphoma. The drug brentuximab vedotin replaces two older drugs in the standard chemo mix, with the goal of achieving a faster complete response on PET scans and reducing the need for radiation therapy. About 96 participants will be enrolled across China, and the study will track how well the cancer responds and how long patients stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.